Skip to main content

Key new drugs help close out 2024

New biologics for breast cancer, hemophilia, and a rare form of heart disease are poised to add competition and choice in these classes.

Welcome to the Fall 2024 Notable New Drugs Report

New treatments target relatively small, hard-to-treat patient populations with big drug spend.

This edition of the report showcases:

  • A first-in-class treatment for both A and B hemophilia which can reduce the frequency of bleeding episodes.
  • A new addition to standard breast cancer therapy with improved outcomes for people with HR-positive breast cancer.
  • A new drug to treat a rare congenital heart disease can reduce the risk of death by 57%.

Don't want to read the full report? Download the summary.

Related healthcare insights

View all

Advancing health equity: How Optum Rx is overcoming challenges

Thought leaders discuss the intentional vigilance needed to overcome obstacles impeding better access to healthcare for all.

What’s changing the PBM industry?

Learn from Optum Rx thought leaders how access, affordability and transparency have become imperatives for pharmacy benefit management.

E-book

3 steps to slash medication costs

This is your employer guide to reducing your healthcare spending.